Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia

Pembrolizumab treatment of melanoma and concomitant sAML resulted in a significant platelet response and clearance of IDH1 mutation. Pembrolizumab therapy and response was associated with an increased PD-L1 expression on acute myeloid leukemia blasts and T cells.

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Kubasch, Anne Sophie, Wehner, Rebekka, Bazzurri, Serena, Tunger, Antje, Stasik, Sebastian, Garzarolli, Marlene, Meinel, Jörn, Baretton, Gustavo, Meier, Friedegund, Thiede, Christian, Schmitz, Marc, Platzbecker, Uwe
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2018
Konular:
Exceptional Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5998917/
https://ncbi.nlm.nih.gov/pubmed/29844203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017014811
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller